Is Sun wooing Lizhu for a larger presence in China?
This article was originally published in Scrip
Even as Sun Pharmaceutical Industries assimilates Takeda-owned URL's generic business (scripintelligence.com, 18 December 2012), there is speculation that the Indian firm may also be keen to build up its branded generics business in China, possibly via an alliance or even a partial acquisition.
You may also be interested in...
Evolving regulations and emerging opportunities appear to have put China firmly on the radar of several frontline Indian firms. Sun Pharma is the latest to join those seeking a larger play in the Asian market.
Mayne Pharma has announced the appointment of pharma industry veteran Shawn O’Brien as CEO, replacing outgoing delegate Scott Richards. Plus, Hikma has appointed two new female board members, in line with gender diversity targets set by the UK Financial Conduct Authority.
MagGenome, an Indian biotech which develops nanoparticle-based products, is in the early stage of research for a vaccine adjuvant. Scrip spoke to founder Sam Santhosh and CEO and chief scientific officer C N Ramchand to gauge the promise of nanotechnology and the environment in India for cell and gene therapies, among other topics, in this wide-ranging audio interview.